الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 160 |  |  |
| | | from | 160 | | |
Abstract
Nilotinib is a potent and selective BCR-ABL1kinase inhibitor, which binds to the fusion protein via an additional lipophilic pocket adjacent to the ATP-binding site of ABL1 and is a 30-fold more potent inhibitor of BCR-ABL1 compared to imatinib.
The aim of the work is to assess the early reach ability of major molecular response (MMR) in chronic phase of CML patients on first(1st) and second(2nd) generation TKI(as regard 1st and 2nd line of treatment.
In this study, a retrospective study was done in the hematology unit at the department of internal medicine, Faculty of medicine, Ain Shams University on 100 CML patients, were sub divided into 3 groups Groups 1: included 40 patients on first generation TKI (imitinib 400mg), Groups 2 included 40 patients shifted from 1st generation (imitinib 400mg) to 2nd generation (nilotinib 300mg) Groups3included20 patients on 2nd generation (nilotinib) from the start.
All the patients were in chronic phase chronic myeloid leukemia, informed written consent was taken from all the patients for participation in this study.
All patients l groups withdrew blood samples for measurement of PCR for BCR-ABL.
The study data were collected from medical notes and laboratory data.
All patients were followed up for 1year.
After recording the results and using the suitable statistic methods, we found that
In our study, there was no statistically significant difference between age and sex and MMR.
In our study more patients with chronic myeloid leukemia in chronic phase achieve EMR on frontline nilotinib than imatinib.
In our study molecular and cytogenetic responses to nilotinib were superior to imatinib and more patients achieved undetectable levels of disease with nilotinib
At the end of our study, we suggest performing the study on a larger number of CML patients at different disease phases for longer duration.